Cesca Therapeutics is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine in hematology/oncology, cardio/vascular applications and orthopedics. The newly formed advisory board will consist of scientists, researchers and clinicians drawn from the regenerative medicine field.
Dr. Hamburg is board-certified in hematology, medical oncology and internal medicine. He is a partner at Beverly Hills, Calif.-based Tower Hematology Oncology Medical Group.
More Articles on Devices:
5 Key Results: LDR’s Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE’s Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018
